Kwality Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Kwality Pharmaceuticals (KPL) reported revenue ₹158 Cr and net profit ₹25 Cr — revenue +35.0% YoY. View Kwality Pharmaceuticals yearly highs lows for the annual high/low range and current price position.
KPL Quarterly Results — Revenue, Profit & EPS Highlights
Kwality Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Kwality Pharmaceuticals share price chart.
- Revenue of ₹158 Cr in Mar 2026 (-3.1% vs Jun 2026, +35.0% vs Mar 2025)
- Net Profit of ₹25 Cr in Mar 2026 (-3.8% vs Jun 2026, +66.7% vs Mar 2025)
- EBITDA of ₹40 Cr in Mar 2026 (-4.8% vs Jun 2026)
- Operating Margin of 25.0% in Mar 2026 (+0.0pp vs Jun 2026)
- Earnings Per Share of ₹24.39 in Mar 2026 (-1.2% vs Jun 2026)
Kwality Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
KPL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 158 | 163 | 112 | 117 | 112 | -3.1% | 35.0% |
| Net Profit (₹ Cr) | 25 | 26 | 14 | 15 | 12 | - | - |
| EBITDA (₹ Cr) | 40 | 42 | 26 | 27 | 25 | - | - |
| EPS (₹) | 24.39 | 24.69 | 13.60 | 13.95 | 11.49 | - | - |
| Operating Margin (%) | 25.0% | 25.0% | 23.0% | 22.0% | 22.0% | - | - |
KPL Share Price Trend — 1-Year Movement Across Quarterly Results
Kwality Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse KPL FII DII holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
KPL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Kwality Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores